Valuation: Amgen Inc.

Capitalization 179B 154B 141B 133B 246B 17,284B 250B 1,670B 653B 8,159B 672B 657B 28,419B P/E ratio 2026 *
21.6x
P/E ratio 2027 * 19.6x
Enterprise value 220B 189B 173B 164B 303B 21,266B 307B 2,055B 804B 10,039B 826B 809B 34,967B EV / Sales 2026 *
5.83x
EV / Sales 2027 * 5.52x
Free-Float
99.78%
Yield 2026 *
3.04%
Yield 2027 * 3.21%
1 day+0.25%
1 week-1.45%
Current month-4.24%
1 month-5.31%
3 months-11.52%
6 months-1.34%
Current year+1.30%
1 week 320.96
Extreme 320.965
336.23
1 month 320.52
Extreme 320.52
350.69
Current year 318.21
Extreme 318.21
391.29
1 year 267.83
Extreme 267.83
391.29
3 years 211.71
Extreme 211.71
391.29
5 years 198.64
Extreme 198.64
391.29
10 years 133.64
Extreme 133.64
391.29
Manager TitleAgeSince
Chief Executive Officer 63 2012-04-30
Director of Finance/CFO 67 2019-12-31
Chief Operating Officer 59 2016-07-24
Director TitleAgeSince
Chairman 63 2012-12-31
Director/Board Member 65 2011-12-31
Director/Board Member 71 2011-12-31
Change 5d. change 1-year change 3-years change Capi.($)
+0.25%-1.45%+20.57%+48.41% 179B
-0.25%+0.31%+36.39%+130.32% 911B
-0.30%-0.48%+49.24%+44.31% 554B
-0.68%+1.82%+14.85%+46.30% 378B
-0.42%+2.53%+24.56%+13.82% 333B
+0.50%+1.34%+33.90%+16.15% 288B
-0.42%+1.49%+27.07%+30.97% 287B
-1.09%-0.40%+44.93%-2.16% 282B
+0.31%-3.61%-36.78%-49.84% 198B
+0.15%-1.77%+19.78%+65.76% 162B
Average -0.24%+0.67%+23.45%+34.40% 357.15B
Weighted average by Cap. -0.37%+1.04%+29.13%+52.56%

Financials

2026 *2027 *
Net sales 37.79B 32.5B 29.75B 28.11B 51.94B 3,650B 52.78B 353B 138B 1,723B 142B 139B 6,002B 38.75B 33.32B 30.51B 28.82B 53.26B 3,743B 54.11B 362B 142B 1,767B 145B 142B 6,154B
Net income 8.26B 7.11B 6.51B 6.15B 11.36B 798B 11.54B 77.13B 30.18B 377B 31.01B 30.36B 1,312B 9.04B 7.77B 7.12B 6.72B 12.42B 873B 12.62B 84.37B 33.01B 412B 33.93B 33.21B 1,436B
Net Debt 41.23B 35.46B 32.46B 30.67B 56.67B 3,982B 57.58B 385B 151B 1,880B 155B 151B 6,548B 35.08B 30.17B 27.62B 26.09B 48.22B 3,388B 48.99B 327B 128B 1,600B 132B 129B 5,571B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
26-05-20 331.57 $ +0.25% 4,073,872
26-05-19 330.75 $ +1.96% 3,040,404
26-05-18 324.39 $ -0.59% 2,030,276
26-05-15 326.31 $ -2.95% 3,447,804
26-05-14 336.23 $ -0.07% 2,041,584
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
331.57USD
Average target price
352.23USD
Spread / Average Target
+6.23%

Quarterly revenue - Rate of surprise